Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects

To investigate the influence of food and administration of an antacid (aluminum-magnesium hydroxide) or ranitidine on the absorption of BAY 59-7939 (rivaroxaban), 4 randomized studies were performed in healthy male subjects. In 2 food interaction studies, subjects received BAY 59-7939, either as two...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacology Vol. 46; no. 5; p. 549
Main Authors Kubitza, Dagmar, Becka, Michael, Zuehlsdorf, Michael, Mueck, Wolfgang
Format Journal Article
LanguageEnglish
Published England 01.05.2006
Subjects
Online AccessGet more information

Cover

Loading…
Abstract To investigate the influence of food and administration of an antacid (aluminum-magnesium hydroxide) or ranitidine on the absorption of BAY 59-7939 (rivaroxaban), 4 randomized studies were performed in healthy male subjects. In 2 food interaction studies, subjects received BAY 59-7939, either as two 5-mg tablets (fasted and fed), four 5-mg tablets (fasted), or one 20-mg tablet (fasted and fed). In 2 drug interaction studies, BAY 59-7939 (six 5-mg tablets) was given alone or with ranitidine (150 mg twice daily, preceded by a 3-day pretreatment phase) or antacid (10 mL). Plasma samples were obtained to assess pharmacokinetic and pharmacodynamic parameters of BAY 59-7939. In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939. Compared with baseline, BAY 59-7939 resulted in a relative increase in maximum prothrombin time (PT) prolongation of 44% (10 mg) and 53% (20 mg) in the fasted state, compared with 53% and 83% after food. Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type. No significant difference in C(max) and AUC was observed with coadministration of BAY 59-7939 and ranitidine or antacid.
AbstractList To investigate the influence of food and administration of an antacid (aluminum-magnesium hydroxide) or ranitidine on the absorption of BAY 59-7939 (rivaroxaban), 4 randomized studies were performed in healthy male subjects. In 2 food interaction studies, subjects received BAY 59-7939, either as two 5-mg tablets (fasted and fed), four 5-mg tablets (fasted), or one 20-mg tablet (fasted and fed). In 2 drug interaction studies, BAY 59-7939 (six 5-mg tablets) was given alone or with ranitidine (150 mg twice daily, preceded by a 3-day pretreatment phase) or antacid (10 mL). Plasma samples were obtained to assess pharmacokinetic and pharmacodynamic parameters of BAY 59-7939. In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939. Compared with baseline, BAY 59-7939 resulted in a relative increase in maximum prothrombin time (PT) prolongation of 44% (10 mg) and 53% (20 mg) in the fasted state, compared with 53% and 83% after food. Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type. No significant difference in C(max) and AUC was observed with coadministration of BAY 59-7939 and ranitidine or antacid.
Author Mueck, Wolfgang
Becka, Michael
Zuehlsdorf, Michael
Kubitza, Dagmar
Author_xml – sequence: 1
  givenname: Dagmar
  surname: Kubitza
  fullname: Kubitza, Dagmar
  email: dagmar.kubitza@bayerhealthcare.com
  organization: Institute of Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany. dagmar.kubitza@bayerhealthcare.com
– sequence: 2
  givenname: Michael
  surname: Becka
  fullname: Becka, Michael
– sequence: 3
  givenname: Michael
  surname: Zuehlsdorf
  fullname: Zuehlsdorf, Michael
– sequence: 4
  givenname: Wolfgang
  surname: Mueck
  fullname: Mueck, Wolfgang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16638738$$D View this record in MEDLINE/PubMed
BookMark eNo1UE1LAzEUzKFiP_TuSXJU6Go-utnNsZb6AQUvPeipJJvETWmTkqRif5D_0-yq8ODNzBvmwYzBwHmnAbjC6A7jqrpHiGNSIYQYqRlHswEYdVLRaUMwjnGLEGazEp-DIWaM1hWtR-B7aYxuEvQGGu_VFAqXJ4nG9ljB1Gr4THrtwzsbEwzC2WSVdRp619-FjD4cks005zzM32HJi4pTDm-C_RTBfwkp3G0f7oPYTaGyoftqRJN8gG8CWtdaaTOZZghbLXapPcF4lNvsixfgzIhd1Jd_ewLWj8v14rlYvT69LOarwlLMWSExkbpBtTK4pNxIpCgXJZddIdhQUtbIKEUM1grPNK2zt8w9lKhumCGaTMD1b-zhKPdabQ7B7kU4bf7rIj9R22wA
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1177/0091270006286904
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 16638738
Genre Randomized Controlled Trial
Journal Article
GroupedDBID ---
.55
.GJ
05W
0R~
123
18M
1CY
1OB
1OC
29K
33P
34G
39C
3O-
3SF
4.4
52U
52V
53G
5RE
8-1
A00
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAYOK
AAZKR
ABCUV
ABJNI
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACXBN
ACXME
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADMGS
ADNMO
ADOZA
ADXAS
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AHBTC
AHMBA
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AUVAJ
AVWKF
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BOGZA
BRXPI
C45
CAG
CGR
COF
CS3
CUY
CVF
D-I
DCZOG
DPXWK
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECM
EIF
EJD
EMOBN
F5P
FEDTE
FUBAC
G-S
GODZA
GWYGA
H13
HF~
HGLYW
HVGLF
IAO
IEA
IHR
INH
INR
IVC
KBYEO
LATKE
LEEKS
LH4
LOXES
LSO
LUTES
LW6
LYRES
M4V
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N9A
NPM
O66
O9-
OVD
P2P
P2W
PALCI
PQQKQ
R.K
RIWAO
RJQFR
ROL
SAMSI
SUPJJ
SV3
TEORI
VH1
WBKPD
WH7
WIH
WIJ
WIK
WOHZO
WOIKV
WPGGZ
WXSBR
WYJ
X7M
YCJ
ZGI
ZXP
ZZTAW
ID FETCH-LOGICAL-i3196-b12bec08df1539fb0d39a59b28691f32580fdd2f1ed14e38ec05387508c6f2e2
ISSN 0091-2700
IngestDate Wed Feb 19 01:53:20 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-i3196-b12bec08df1539fb0d39a59b28691f32580fdd2f1ed14e38ec05387508c6f2e2
PMID 16638738
ParticipantIDs pubmed_primary_16638738
PublicationCentury 2000
PublicationDate 2006-May
PublicationDateYYYYMMDD 2006-05-01
PublicationDate_xml – month: 05
  year: 2006
  text: 2006-May
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of clinical pharmacology
PublicationTitleAlternate J Clin Pharmacol
PublicationYear 2006
SSID ssj0016451
Score 2.3024352
Snippet To investigate the influence of food and administration of an antacid (aluminum-magnesium hydroxide) or ranitidine on the absorption of BAY 59-7939...
SourceID pubmed
SourceType Index Database
StartPage 549
SubjectTerms Adult
Aluminum Hydroxide - pharmacology
Antacids - pharmacology
Cross-Over Studies
Dietary Carbohydrates - pharmacology
Dietary Fats - pharmacology
Drug Combinations
Drug Interactions
Factor Xa Inhibitors
Fasting - metabolism
Food-Drug Interactions
Histamine H2 Antagonists - pharmacology
Humans
Intestinal Absorption - drug effects
Magnesium Hydroxide - pharmacology
Male
Morpholines - adverse effects
Morpholines - blood
Morpholines - pharmacokinetics
Morpholines - pharmacology
Prothrombin Time
Ranitidine - pharmacology
Rivaroxaban
Thiophenes - adverse effects
Thiophenes - blood
Thiophenes - pharmacokinetics
Thiophenes - pharmacology
Title Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/16638738
Volume 46
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6lcOGCeFNemgOqQI7Bz8R7bBEoAhX1EEQ4Vbve3dSitaM4QbT_h7_G72DGu46t0CLgYq280cTxfNn5dl7L2HO0wGEUCO0bbsbkrUr9TKbCjxWiKTZBKA1FdA8_jiafkvezdDYY_OxlLa1X8lV-cWldyf9oFe-hXqlK9h80uxGKN3CM-sUrahivf6Vj13oY-Z5xmTOCcotXIi9Um5ZJxHISNXfnFbXJ9ZbU8aJQRC9tpMATsq6Wi5Y7Hux_8VLu41-KE_9cFt_EsvouJLlKufsSquunobWI7tQebya8ojwpZLGyToCidHWW5169luTxqa8gw5sCzUXXSnvj7P-wRokXNjAl5mdik098oPOvYjv5n7zga31yWqtqaS6ZPFxrawI-V6dmLpzl7jk-2jTDdjHnIZXTBf3F3Pkzi364vFmZU9sZ9XeL0cSsSRaJoorSEbcHIvcAtDhrEBQiPcvGthvNn2e3eni3UztsB3czdDwr-ZRcrGuUpPZcR_dzumD66-3Hoha3TtTWNqihQ9Nb7KZTHexbUN5mA13eYXtHVnvnQ5h2dX31EPbgqKfXu-yHRS5UBgi5QxAlONzSWAGiEiYRdKiFDrVQlc18h1qSg6gFh1p40cPsy0Y44XUIFq1g0QozARu0DnEIDqvQYvUem757O30z8d2BIX5BlsSXYYRLUpApg3acGxmomIuUS3p5oYmjNAuMUpEJtQoTHWf4WbT3yJmzfGQiHd1n18qq1A8ZIGPTAUd-nGmk2GOd4bbHJLHJhchUnox32QP79o8XtinMcauXR1fOPGY3Ohg_YdcNrkL6KVLalXzWIOIXYpedWA
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+food%2C+an+antacid%2C+and+the+H2+antagonist+ranitidine+on+the+absorption+of+BAY+59-7939+%28rivaroxaban%29%2C+an+oral%2C+direct+factor+Xa+inhibitor%2C+in+healthy+subjects&rft.jtitle=Journal+of+clinical+pharmacology&rft.au=Kubitza%2C+Dagmar&rft.au=Becka%2C+Michael&rft.au=Zuehlsdorf%2C+Michael&rft.au=Mueck%2C+Wolfgang&rft.date=2006-05-01&rft.issn=0091-2700&rft.volume=46&rft.issue=5&rft.spage=549&rft_id=info:doi/10.1177%2F0091270006286904&rft_id=info%3Apmid%2F16638738&rft_id=info%3Apmid%2F16638738&rft.externalDocID=16638738
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-2700&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-2700&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-2700&client=summon